JP6853178B2 - ＦｃＲｎ抗体およびその使用方法 - Google Patents

ＦｃＲｎ抗体およびその使用方法 Download PDF

Info

Publication number
JP6853178B2
JP6853178B2 JP2017539428A JP2017539428A JP6853178B2 JP 6853178 B2 JP6853178 B2 JP 6853178B2 JP 2017539428 A JP2017539428 A JP 2017539428A JP 2017539428 A JP2017539428 A JP 2017539428A JP 6853178 B2 JP6853178 B2 JP 6853178B2
Authority
JP
Japan
Prior art keywords
sequence
antibody
seq
fcrn
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017539428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504907A5 (enExample
JP2018504907A (ja
Inventor
マリリン ケーリー
マリリン ケーリー
デビッド ジェイ． キング
デビッド ジェイ． キング
レオナ イー． リング
レオナ イー． リング
ジェイムズ ザ サード ミーダー
ジェイムズ ザ サード ミーダー
スチャリタ ロイ
スチャリタ ロイ
アンソニー マニング
アンソニー マニング
Original Assignee
モメンタ ファーマシューティカルズ インコーポレイテッド
モメンタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モメンタ ファーマシューティカルズ インコーポレイテッド, モメンタ ファーマシューティカルズ インコーポレイテッド filed Critical モメンタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2018504907A publication Critical patent/JP2018504907A/ja
Publication of JP2018504907A5 publication Critical patent/JP2018504907A5/ja
Application granted granted Critical
Publication of JP6853178B2 publication Critical patent/JP6853178B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
JP2017539428A 2015-01-30 2016-01-29 ＦｃＲｎ抗体およびその使用方法 Active JP6853178B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562110071P 2015-01-30 2015-01-30
US62/110,071 2015-01-30
US201562258082P 2015-11-20 2015-11-20
US62/258,082 2015-11-20
PCT/US2016/015720 WO2016123521A2 (en) 2015-01-30 2016-01-29 Fcrn antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021002601A Division JP7224382B2 (ja) 2015-01-30 2021-01-12 ＦｃＲｎ抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2018504907A JP2018504907A (ja) 2018-02-22
JP2018504907A5 JP2018504907A5 (enExample) 2019-03-14
JP6853178B2 true JP6853178B2 (ja) 2021-03-31

Family

ID=56544538

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017539428A Active JP6853178B2 (ja) 2015-01-30 2016-01-29 ＦｃＲｎ抗体およびその使用方法
JP2021002601A Active JP7224382B2 (ja) 2015-01-30 2021-01-12 ＦｃＲｎ抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021002601A Active JP7224382B2 (ja) 2015-01-30 2021-01-12 ＦｃＲｎ抗体およびその使用方法

Country Status (21)

Country Link
US (3) US10676526B2 (enExample)
EP (2) EP4286011A3 (enExample)
JP (2) JP6853178B2 (enExample)
KR (3) KR20250052465A (enExample)
CN (13) CN113384693B (enExample)
AU (2) AU2016211280B2 (enExample)
DK (1) DK3250610T3 (enExample)
ES (1) ES2962824T3 (enExample)
FI (1) FI3250610T3 (enExample)
HR (1) HRP20231399T1 (enExample)
HU (1) HUE063778T2 (enExample)
IL (1) IL252837B (enExample)
LT (1) LT3250610T (enExample)
NZ (1) NZ772383A (enExample)
PL (1) PL3250610T3 (enExample)
PT (1) PT3250610T (enExample)
RS (1) RS64768B1 (enExample)
SG (2) SG10202007232WA (enExample)
SI (1) SI3250610T1 (enExample)
SM (1) SMT202300365T1 (enExample)
WO (1) WO2016123521A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019526540A (ja) * 2016-07-29 2019-09-19 モメンタ ファーマシューティカルズ インコーポレイテッド Ｆｃｒｎ抗体及びその使用方法
JP2021531346A (ja) * 2018-07-20 2021-11-18 モメンタ ファーマシューティカルズ インコーポレイテッド Ｆｃｒｎ抗体の組成物およびその使用の方法
US11732047B2 (en) 2015-01-30 2023-08-22 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
US11773168B2 (en) 2017-12-13 2023-10-03 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
US12528867B2 (en) 2018-07-20 2026-01-20 Momenta Pharmaceuticals, Inc. FCRN antibody compositions

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016014810B1 (pt) 2013-12-24 2023-12-26 Argenx Bvba Antagonistas de fcrn e métodos de uso
EP3155013B1 (en) * 2014-06-12 2019-03-27 F. Hoffmann-La Roche AG Method for selecting antibodies with modified fcrn interaction
BR112019026694A2 (pt) * 2017-06-15 2020-06-23 UCB Biopharma SRL Método para o tratamento da trombocitopenia imune
AU2018380979B2 (en) 2017-12-08 2023-07-20 argenx BV Use of FcRn antagonists for treatment of generalized myasthenia gravis
SG11202011849VA (en) 2018-06-08 2020-12-30 Argenx Bvba Compositions and methods for treating immune thrombocytopenia
BR112021007092A2 (pt) 2018-10-16 2021-08-03 UCB Biopharma SRL método para o tratamento de miastenia grave
JP7565951B2 (ja) 2019-06-07 2024-10-11 アルジェニクス ビーブイ 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤
CA3148826A1 (en) * 2019-08-01 2021-02-04 Janssen Biotech, Inc. Fcrn antibodies and methods of use thereof
TW202132346A (zh) * 2019-11-19 2021-09-01 瑞士商依牧諾萬科學有限公司 使用抗-fcrn抗體治療溫抗體型自體免疫性溶血性貧血之方法
EP4087875B1 (en) 2020-01-08 2024-08-28 Argenx BV Antagonists of human neonatal fc receptor (fcrn) for treating pemphigus disorders
AU2021376364A1 (en) * 2020-11-06 2023-06-22 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
CN114410643B (zh) * 2021-02-02 2024-08-02 百奥赛图(北京)医药科技股份有限公司 FcRn基因人源化的非人动物及其构建方法和应用
JP7755725B2 (ja) * 2021-08-13 2025-10-16 ジャンスー バイオジェッテイ バイオテクノロジー カンパニー リミテッド Ｆｃｒｎを特異的に認識する抗体およびその使用
WO2023030501A1 (zh) * 2021-09-03 2023-03-09 舒泰神（北京）生物制药股份有限公司 特异性识别FcRn的抗体及其应用
KR20250018382A (ko) 2022-05-30 2025-02-05 한올바이오파마주식회사 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편
JP2025518971A (ja) 2022-06-15 2025-06-19 アルジェニクス ビーブイ ｐＨ依存性ＨＳＡ結合分子及び使用方法
CN120693177A (zh) 2023-02-04 2025-09-23 动量制药公司 用于治疗胎儿和新生儿溶血性疾病的组合物和方法
TW202527982A (zh) 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2025186787A1 (en) 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101721362B (zh) 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
WO2005013912A2 (en) * 2003-08-08 2005-02-17 The Research Foundation Of State University Of Newyork Anti-fcrn antibodies for treatment of auto/allo immune conditions
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
US20090110681A1 (en) 2005-03-08 2009-04-30 Pfizer, Inc. Anti-M-CSF Antibody Compositions
WO2007087289A2 (en) 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
CN101421297A (zh) * 2006-02-17 2009-04-29 森托尼克斯制药有限公司 阻断lgG对FcRn的结合的肽
CA2644405A1 (en) * 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CN108467431A (zh) * 2008-04-25 2018-08-31 戴埃克斯有限公司 针对fcrn的抗体及其用途
CN102549016B (zh) * 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
PH12013502378A1 (en) * 2011-06-02 2014-01-06 Dyax Corp Fc RECEPTOR BINDING PROTEINS
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US20130323242A1 (en) 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
US9844594B2 (en) 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
EP3719122A1 (en) 2013-05-02 2020-10-07 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
HRP20231399T1 (hr) 2015-01-30 2024-02-16 Momenta Pharmaceuticals, Inc. Fcrn antitijela i načini njihove uporabe
DK3268391T3 (da) 2015-03-09 2021-09-13 Argenx Bvba Fremgangsmåder til reduktion af serumniveauer af Fc-indeholdende midler ved anvendelse af FcRn-antagonister
CA3022547A1 (en) 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
KR20240151878A (ko) 2016-07-29 2024-10-18 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
AU2018380979B2 (en) 2017-12-08 2023-07-20 argenx BV Use of FcRn antagonists for treatment of generalized myasthenia gravis
WO2019118791A1 (en) 2017-12-13 2019-06-20 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
JOP20210013A1 (ar) 2018-07-20 2021-01-19 Momenta Pharmaceuticals Inc تركيبات جسم مضاد fcrn
EA202190335A1 (ru) 2018-07-20 2021-06-11 Момента Фармасьютикалз, Инк. Композиции антител против fcrn и способы их применения

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11732047B2 (en) 2015-01-30 2023-08-22 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
JP2019526540A (ja) * 2016-07-29 2019-09-19 モメンタ ファーマシューティカルズ インコーポレイテッド Ｆｃｒｎ抗体及びその使用方法
US11345751B2 (en) 2016-07-29 2022-05-31 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
JP7094941B2 (ja) 2016-07-29 2022-07-04 モメンタ ファーマシューティカルズ インコーポレイテッド Ｆｃｒｎ抗体及びその使用方法
US11773168B2 (en) 2017-12-13 2023-10-03 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
JP2021531346A (ja) * 2018-07-20 2021-11-18 モメンタ ファーマシューティカルズ インコーポレイテッド Ｆｃｒｎ抗体の組成物およびその使用の方法
JP7457704B2 (ja) 2018-07-20 2024-03-28 モメンタ ファーマシューティカルズ インコーポレイテッド Ｆｃｒｎ抗体の組成物およびその使用の方法
US12528867B2 (en) 2018-07-20 2026-01-20 Momenta Pharmaceuticals, Inc. FCRN antibody compositions

Also Published As

Publication number Publication date
JP7224382B2 (ja) 2023-02-17
ES2962824T3 (es) 2024-03-21
CN118667015A (zh) 2024-09-20
CN113384693B (zh) 2025-07-04
KR20230007545A (ko) 2023-01-12
AU2016211280B2 (en) 2021-11-25
NZ772383A (en) 2024-11-29
FI3250610T3 (fi) 2023-11-01
US20240158508A1 (en) 2024-05-16
PT3250610T (pt) 2023-11-13
CN118667013A (zh) 2024-09-20
CN113384693A (zh) 2021-09-14
SMT202300365T1 (it) 2023-11-13
US10676526B2 (en) 2020-06-09
US20180016334A1 (en) 2018-01-18
EP4286011A2 (en) 2023-12-06
SG10202007232WA (en) 2020-09-29
HRP20231399T1 (hr) 2024-02-16
AU2022201145A1 (en) 2022-03-17
DK3250610T3 (da) 2023-10-30
US11732047B2 (en) 2023-08-22
CN118638229A (zh) 2024-09-13
EP3250610A4 (en) 2018-08-22
HUE063778T2 (hu) 2024-01-28
CN107567460A (zh) 2018-01-09
SG11201705475QA (en) 2017-08-30
KR20170109020A (ko) 2017-09-27
US20200299382A1 (en) 2020-09-24
NZ733097A (en) 2024-07-05
EP3250610A2 (en) 2017-12-06
LT3250610T (lt) 2023-09-25
EP4286011A3 (en) 2024-02-14
JP2021061854A (ja) 2021-04-22
WO2016123521A3 (en) 2016-09-22
CN107567460B (zh) 2021-04-23
CN118638230A (zh) 2024-09-13
IL252837B (en) 2021-10-31
SI3250610T1 (sl) 2023-11-30
AU2016211280A1 (en) 2017-07-13
CN118667011A (zh) 2024-09-20
CN118667012A (zh) 2024-09-20
JP2018504907A (ja) 2018-02-22
BR112017015287A2 (pt) 2018-01-16
EP3250610B1 (en) 2023-08-09
WO2016123521A2 (en) 2016-08-04
KR102483016B1 (ko) 2023-01-03
CN118652337A (zh) 2024-09-17
CN118667010A (zh) 2024-09-20
AU2022201145B2 (en) 2024-11-14
RS64768B1 (sr) 2023-11-30
CN118562003A (zh) 2024-08-30
CA2972822A1 (en) 2016-08-04
IL252837A0 (en) 2017-08-31
PL3250610T3 (pl) 2024-01-29
CN118667009A (zh) 2024-09-20
KR102792441B1 (ko) 2025-04-08
CN118667014A (zh) 2024-09-20
KR20250052465A (ko) 2025-04-18

Similar Documents

Publication Publication Date Title
JP6853178B2 (ja) ＦｃＲｎ抗体およびその使用方法
US20230049725A1 (en) FcRn Antibodies and Methods of Use Thereof
HK40103769A (en) Fcrn antibodies and methods of use thereof
CA2972822C (en) Fcrn antibodies and methods of use thereof
HK1247218B (en) Fcrn antibodies and methods of use thereof
HK1247218A1 (en) Fcrn antibodies and methods of use thereof
BR122021007991B1 (pt) Uso de anticorpos que se ligam a fcrn humana
BR112017015287B1 (pt) Anticorpos isolados que se ligam a fcrn humano, e composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190129

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190813

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200416

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210112

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210112

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210119

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210311

R150 Certificate of patent or registration of utility model

Ref document number: 6853178

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250